Drug
5-aminolevulinic acid (5-ALA)
5-aminolevulinic acid (5-ALA) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
not_yet_recruiting133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruiting
Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients
NCT06777511
completednot_applicable
Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood
NCT01508741
completedphase_3
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
NCT00241670
Clinical Trials (3)
Showing 3 of 3 trials
NCT06777511
Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients
NCT01508741Not Applicable
Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood
NCT00241670Phase 3
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3